From owner-contents@net.bio.net Sat May 08 12:11:00 1999 Path: biosci!news.stanford.edu!newsfeed.stanford.edu!newsfeed.berkeley.edu!dca1-hub1.news.digex.net!intermedia!dca1-nnrp1.news.digex.net.POSTED!cmhcsys.cmhcsys.com!not-for-mail From: Stevan Harnad Newsgroups: bionet.journals.note,bionet.journals.contents,sci.psychology.announce,comp.publish.electronic.developer,gov.topic.info.systems.epub Subject: Authors' Online Self-Archiving Rights Organization: Southampton University Lines: 100 Sender: daemon@cmhcsys.cmhcsys.com Approved: grohol@coil.com Message-ID: Date: Sat, 08 May 1999 13:05:45 GMT NNTP-Posting-Host: 207.87.223.39 X-Complaints-To: abuse@digex.net X-Trace: dca1-nnrp1.news.digex.net 926168745 207.87.223.39 (Sat, 08 May 1999 09:05:45 EDT) NNTP-Posting-Date: Sat, 08 May 1999 09:05:45 EDT Xref: biosci bionet.journals.note:1250 bionet.journals.contents:3611 ---------- Forwarded message ---------- Date: Sat, 8 May 1999 12:53:35 +0100 (BST) From: Stevan Harnad To: September American Scientist Forum Arthur Smith works for the American Physical Society (APS), the publisher that is (to my knowledge) by far the most enlightened and progressive of all large learned journal publishers today. Their example should and will be followed by others. We should all do whatever we can to further it. On Fri, 7 May 1999 Arthur Smith wrote: > > sh> (2) Is the distinction between allowing free self-archiving of the > sh> final draft on the "home" server and not the "global" server coherent > sh> and enforceable? > > Here's what I understand of the current official policy (I was given > some more information on this today): > > (1) The author, as part of the copyright agreement, can post any > version of the manuscript as created by the author, including the > final version after revisions suggested by referees, to any distribution > service that is either free and public, or if not completely free > is restricted to the author's institution and is not sold commercially > to other institutions. I think the APS's commercial restriction is fully justifiable: As long as APS is footing the bill for it all, there is no reason whatsoever why anyone else should be able to sell the product and profit from it. The author's interests are fully served by having only free distribution rights. > (2) The author, also as part of the copyright agreement, may post the > final APS-created rendition of the article (PDF file, two-column format > and all) to a public web site under the control of the author or author's > institution, accompanied by a statement concerning APS copyright. This > version is not to be posted in other public areas. Very reasonable to require the copyright notice and the clear tagging as an APS-certified paper. However, the interpretation of the difference between my institutional server and, say, the LANL server, is incoherent: I control my LANL paper too; I can delete it any time. Meanwhile, I DON'T control cached versions of my own institutional server, which are automatically generated everywhere. So the LETTER of this distinction turns out, at bottom, to be illogical, not just impracticable. But the SPIRIT of it all seems fine. > The coherence comes in part from requiring the accompanying copyright > statement. Not that it would be easy (or very useful) to police. > > Now we have also seriously considered a license agreement, where the > author retains full copyright. The only thing that is holding > that up is some serious concerns about the validity of the language of > the license under international laws. This may eventually happen, > in which case the restrictions in policy 2 would probably be lifted. Fine. It is clear that the APS has the true interests of its authors and of science at heart, and that these formal details can be worked out. Would that all or even most publishers felt and behaved in this way! > We do want to be on the side of the widest possible distribution for > the BEST scientific articles - somehow, in the past, copyright has > helped to ensure that excellent work is widely distributed, but it may > no longer be the best approach now. Yes, it's the Faustian Bargain I wrote about in '93. > Anyway, this issue really isn't as critical as you make it out to be. > If we did allow it, we would not charge for it, it would just be part > of the copyright or license agreement. That is abundantly clear. The need to make it coherent and explicit is more in the interests of setting a clear example for other publishers than out of any concern about APS's intentions. -------------------------------------------------------------------- Stevan Harnad harnad@cogsci.soton.ac.uk Professor of Cognitive Science harnad@princeton.edu Department of Electronics and phone: +44 1703 592-582 Computer Science fax: +44 1703 592-865 University of Southampton http://www.cogsci.soton.ac.uk/~harnad/ Highfield, Southampton http://www.princeton.edu/~harnad/ SO17 1BJ UNITED KINGDOM ftp://ftp.princeton.edu/pub/harnad/ '`'`'`'`'`'`'`'`'`'`'`'`'`''`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'`'` sci.psychology.announce is a moderated newsgroup. Before submitting an article, please read the guidelines which are posted here bimonthly or the charter on the Web at http://www.grohol.com/spa/ Submissions are acknowledged automatically. From owner-contents@net.bio.net Sat May 29 04:36:00 1999 Path: biosci!biosci!not-for-mail From: BIOSCI Administrator Newsgroups: bionet.journals.contents Subject: Biotecnologia Aplicada, vol. 16, no. 02, 1999 Date: 28 May 1999 22:36:50 -0700 Organization: BIOSCI International Newsgroups for Molecular Biology Lines: 414 Sender: daemon@net.bio.net Approved: biosci-help@net.bio.net Distribution: world Message-ID: <7inudi$g72@net.bio.net> NNTP-Posting-Host: net.bio.net CC BIOTECNOLOGIA APLICADA CC Vol. 16 No. 2 (April-June, 1999) CC ISSN 0864-4551 (printed) CC ISSN 1027-2852 (electronic) CC Copyright 1999, Elfos Scientiae. CC Founded in 1983 and published as Interferon y CC Biotecnologia until 1990, Biotecnologia Aplicada is a CC peer-reviewed scientific journal. It appears four times CC per year, sponsored by the Ibero-Latin-American Society CC of Biotechnology Applied to Health. CC BIOTECNOLOGIA APLICADA is a vehicle of Iberian-Latin- CC American scientists working in different fields of modern CC biotechnology for the diffusion of their experiences and CC results. Some of the main topics that are considered for CC publication are the following: CC a) Molecular genetics and recombinant DNA technology; CC b) Therapeutic and prophylactic uses of molecules CC obtained by biotechnological methods; CC c) Immunotechnology and development of diagnostic CC methods; CC d) Chemistry, biochemistry and design of molecules with CC biological activity; CC e) Application of recombinant DNA techniques and its CC products in agriculture and animal science; CC f) Transgenesis; CC g) Fermentation, recovery and purification of biotech- CC nological products; CC h) Scaling-up, plant design and economic evaluation; CC i) Control and automation of processes. CC All rights reserved. No part of this publication may be CC reproduced, stored or transmitted in any form or by any CC means without the prior permission of the Publisher. By CC submitting a manuscript the authors agree that the CC copyright for their article is transferred to the CC Publisher if and when the article is accepted for CC publication. The points of view expressed in the Journal CC are exclusive responsibility of the authors. CC This journal is indexed by the following publications: CC Biosis, Current Biotechnology Abstracts, Derwent Biotech- CC nology Abstracts, Cambridge Scientific Abstracts, CC Chemical Abstracts, Biological Abstracts, EMBASE/Excerpta CC Medica, Elsevier BIOBASE/Current Awareness in Biological CC Sciences, Periódica, LilaCS, Bio-Journals (Internet). CC Correspondence and subscriptions CC Ave. 31 entre 158 y 190, CC Cubanacan, Playa CC Ciudad de La Habana, CC Apdo. 6072, Habana 6, Cuba. CC Telephones: (53-7) 33 1917 / 21 8466 / 21 8164 CC Fax: (53-7) 33 1917 / 21 8070 / 33 6008 CC E-mail: elfos@cigb.edu.cu CC Full papers are available online through BIOLINE System CC (Internet) through the WWW or by e-mail. Annual subscrip- CC tion or single document purchase are possible. Contact CC the following for further information: CC URL:http://www.bd.org.br/bioline/ CC E-mail address: bio@biostrat.demon.co.uk AU Javier Menéndez IN División de Biotecnología Industrial. Centro de Ingeniería Genética y Biotecnología. AP 6162, CP 10600. Ciudad de La Habana, Cuba. Fax: (53-7) 33 6008; E-mail: yeastlab@cigb.edu.cu TI Piruvato-carboxilasa de levadura DE pyruvate carboxilase DE promoters DE PYC1 DE PYC2 DE yeast SO Biotecnología Aplicada 1999;16:75-82 AB Pyruvate carboxylase plays an important role in intermediary metabolism, catalyzing the formation of oxaloacetate from pyruvate and HCO3-. It thus provides oxaloacetate for gluconeogenesis and for replenishing tricarboxylic acid cycle for fatty acid, amino acid and neurotransmitter synthesis. The enzyme is highly conserved and it is found in a great variety of organisms including bacteria, yeasts, fungi and plants, as well as in higher organisms. The yeast Saccharomyces cerevisiae contains two structural genes for pyruvate carboxylase, which are regulated in different ways. On the other hand, Pichia pastoris has only one gene. This protein is a member of a group of biotin-dependent enzymes and the disruption of their coding genes results in the incapacity of the yeast to grow on a minimal medium containing glucose as the sole carbon source. This phenotype led to the isolation of mutants from these two yeasts, which are affected in the glucose repression of a series of genes CC Review article CC Language: Spanish AU Raúl Gómez, Joel Madrazo, Javier González, Glay Chinea, Alexis Mussachio, Armando Rodríguez, Gabriel Padrón IN División de Química-Física, División de Vacunas. Centro de Ingeniería Genética y Biotecnología. AP 6162, Ciudad de La Habana, Cuba. Telf: (53-7) 21 8164; Fax: (53-7) 33 6008; E-mail: raul.gomez@cigb.edu.cu TI Caracterización estructural y funcional de la proteína recombinante P64k de Neisseria meningitidis DE cross-linking DE dihydrolipoamide-dehydrogenase DE flavoprotein DE Neisseria meningitidis SO Biotecnología Aplicada 1999;16:83-87 AB The recombinant protein P64k from the bacterium Neisseria meningitidis has been identified as a dihydrolipoamide dehydrogenase. The enzyme catalyses the stoichiometric oxidation of dihydrolipoamide by nicotinamide adenine dinucleotide, involving a flavin adenine dinucleotide as cofactor. Chemical modification with iodoacetamide indicated the involvement in catalysis of a reversibly reducible disulphide bond. Migration of cross-linked protein in polyacrylamide gel electrophoresis showed that the protein is a functional homodimer. Gel filtration chromatography showed the P64k protein to migrate beyond the expected molecular weight. This abnormal behaviour is discussed taking into account the structure-function relationship CC Research article CC Language: Spanish AU Juan Roca, Masood Ahmad, Subrat Kumar Panda, Guillermo Padrón, Shahid Jameel IN Division of Diagnostics and Immunotechnology. Center for Genetic Engineering and Biotechnology. PO Box 6162, Havana 10600, Cuba. Fax: (53-7) 21 8008; E-mail: diag@cigb.edu.cu. Virology Group. International Center for Genetic Engineering and Biotechnology. PO Box 10504, Aruna Asaf Ali Marg, New Delhi 110067, India. Department of Pathology. All India Institute of Medical Sciences, New Delhi, India TI Hepatitis C Virus Genotyping in Developing Countries: Results from Cuba, India and Turkey DE HCV genotypes DE hepatitis C virus DE PCR SO Biotecnología Aplicada 1999;16:88-92 AB Infection by hepatitis C virus (HCV) results in liver disease with a high rate of associated chronicity. Significant genetic variation is seen among HCV isolates based on nucleotide sequence homologies, which has allowed grouping into a number of genotypes. However, most of the information about HCV genotypes is based on studies from developed countries with less information available from developing countries. Here we present the results of HCV genotype determinations in 128 sera from 74 patients in three countries: Cuba, India and Turkey. An established PCR-based genotyping method was optimized to accurately detect multiple genotypes in a given sample. Type II (1b) HCV, which correlates with more aggressive forms of the disease and lower response rates to interferon was most commonly found in the patients from the countries studied. While the majority of patients (58.1%) were infected with a single genotype, dual infections were also found frequently (28.4%). This report discusses the utility of a genotyping assay and the prevalence of genotypes CC Research Article CC Language: English AU Juan P Martínez-Soriano, Norma E Leyva-López, María E Zavala-Soto, Marie Bères, Diana S Leal-Klevezas IN Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional. Unidad de Biotecnología e Ingeniería Genética de Plantas. AP 629, Irapuato, Gto. México. E-mail: jpms@irapuato.ira.cinvestav.mx Institut National Agronomique Paris-Grignon. 16, rue Claude Bernard 75231 Paris Cedex 05, Francia. Centro de Investigación Biomédica del Noreste, Instituto Mexicano del Seguro Social. San Luis Potosí y 2 de abril, Colonia Independencia, Monterrey, NL México TI Detección molecular del agente causal del síndrome "bola de hilo" de la papa en semillas infectadas y asintomáticas DE diagnosis DE mycoplasma-like organisms DE PCR DE phytoplasmas SO Biotecnología Aplicada 1999;16:93-96 AB Economic losses due to the potato diseases caused by phytoplasmas are of considerable value in Mexico (up to 100% in some cases). "Punta morada" and "bola de hilo" (local names meaning "purple top" and "ball of twine", respectively) are the main syndromes observed in the field. The latter is one of particular interest among potato seed producers because it affects tuber germination when infected tubers are used as seed. Because phytoplasmas cannot be cultured in vitro and their detection by visual inspection, by serological methods or by electron microscopy is inefficient and performed late during disease development, disease eradication is an impossible task. In this report, PCR was used as a new tool to detect early or latent phytoplasma infections in symptomless potato "seeds", which will eventually produce "hair sprouts" CC Research Article CC Language: Spanish AU Carmen E Gómez, Javier J Menéndez, Bianca M García IN División de Biotecnología Industrial, Centro de Ingeniería Genética y Biotecnología. AP 6162, CP 10600, Ciudad de La Habana, Cuba. Teléfonos: (53-7) 21 6022, 21 8164, Fax: (53-7) 21 8070. E-mail: dextranasa@cigb.edu.cu TI Expresión del gen dex en la levadura Kluyveromyces lactis DE dextranase DE gene expression DE Kluyveromyces lactis DE Penicillium minioluteum SO Biotecnología Aplicada 1999;16:97-102 AB In this study, the expression and secretion of dextranase enzyme from the fungus Penicillium minioluteum in the non-conventional yeast Kluyveromyces lactis, was evaluated. The cDNA encoding this protein with its own signal peptide was integrated into the genome of K. lactis strain MW105-2A under the control of the LAC4 promoter. Dextranase was detected by the hydrolysis of blue dextran added to solid growth medium and the enzymatic activity was determined colorimetrically by the DNSA method. Dextranase was efficiently expressed and secreted in this yeast. The obtention of this construction constitutes the first step in the use of dextranase-encoding gene as reporter in gene expression studies in the yeast K. lactis CC Research Article CC Language: Spanish AU Antonieta M Herrera, Dania Vázquez, Leonor Navea, Leonor Lobaina, Diógenes Quintana, Annara Nápoles, Yenela García, Carlos A Duarte IN Vaccine Division, AIDS Department. Center for Genetic Engineering and Biotechnology. PO Box 6162, Havana 10600, Cuba. Phone: (53-7) 21 8008, 21 8466. Fax: (53-7) 21 8070, 33 6008 E-mail: amherrera@cigb.edu.cu Laboratorio de Investigaciones de SIDA, San José, La Habana, Cuba TI Effect of Different Adjuvants and Immunomodulators on the Humoral Immune Response of Rabbits and Mice against HIV-1-derived Multi-epitope Polypeptides DE adjuvants DE HIV DE immunomodulators DE vaccines DE V3 loop SO Biotecnología Aplicada 1999;16:103-108 AB The third variable region (V3 loop) of the human immunodeficiency virus (HIV) external glycoprotein gp120 contains the principal neutralizing domain of this protein. Our group has developed multi-epitope polypeptides (MEP), bearing several copies of the V3 loop from different HIV-1 isolates. These chimeric proteins have been able to elicit broadly reactive neutralizing antibodies when administered in Complete Freund's Adjuvant (CFA). For human vaccines, a less reactogenic adjuvant is required. The MEPs TAB9 and TAB13 contain the V3 region from six and eight HIV-1 isolates, respectively, fused to the amino terminus of the Neisseria meningitidis P64K protein. In this paper we describe the effect of several adjuvants and immunomodulators on the antibody response against these MEPs in rabbits and mice. Oil adjuvants proved to be more efficient in promoting the antibody response against MEPs than Alum, Quil A or combinations of Alum with IL-2 and gIFN. The subclass composition of the antibody response was very dependent on the adjuvant employed. CFA induced high levels of IgG2a and IgG2b, while for the rest of the products IgG1 was predominant. We also concluded that the novel oil adjuvant Montanide ISA720 is as efficient as CFA or Incomplete Freund's Adjuvant in stimulating the humoral response in mice and rabbits and therefore, it was selected for further studies in primates. CC Research Article CC Language: English AU Thelvia I Ramos Gómez, Estela Morales Peralta, Teresa Collazo Mesa, Suany Ojeda Fernández, Aida Bertoli Avella, Luis Heredero Baute IN Centro Nacional de Genética Médica. Centro colaborador de la OMS para el desarrollo de enfoques genéticos en la promoción de la salud. Instituto Superior de Ciencias Médicas de La Habana, Cuba. Ave 31 No. 3102, Playa 16, Ciudad de La Habana, Cuba. Teléfono: (53-7) 21 9511, extensiones 268 y 361 Fax: (53-7) 24 6257; E-mail: cngmed@genmed.giron.sld.cu TI Presencia de la mutación G1138A del gen del R3FCF en un grupo de pacientes acondroplásicos cubanos DE achondroplasia DE autosomal dominant DE FGFR3 DE hipoachondroplasia DE osteochondrodysplasias DE thanatophoric dysplasia SO Biotecnología Aplicada 1999;16:109-111 AB Achondroplasia, inherited as an autosomal dominant trait, is the most common human skeletal dysplasia. Prevalence at birth in Cuba was estimated in 1/25 000. Achondroplasia locus was assigned to chromosome 4p16.3 and includes the coding region for fibroblast growth factor receptor 3 (FGFR3). Two point mutations in exon 10 of the FGFR3 gene (G1138A and G1138C) have been described. These mutations create new restriction sites for Sfc1 (the most frequent mutation) and Msp1. Genomic DNA isolated from blood samples of 40 Cuban patients (24 relatives and 16 sporadic cases) was studied. A region of 164 bp that includes the transmembrane domain of FGFR3 was amplified by PCR and the amplicons were analized with the restriction enzimes Sfc1 and Msp1. All affected individuals showed fragment sizes of 109 and 55 bp corresponding to the digestion by Sfc1; therefore, they had the same mutation G1138A CC Research Article CC Language: Spanish AU Mayte Nerey Olivares, Rolando Ochoa Azze, Juan C Martínez Rodríguez, Tania Licea Verdecia, Xenia Ferriol Marchena, Ana M García Malberti, Rosa Blanco González, Eric Estrada González IN DACTA, Instituto "Finlay". Ave 27 No 19805. AP 16017, CP 11600, La Lisa, Ciudad de La Habana, Cuba. Fax: (53-7) 33 6754; E-mail: ochoa@finlay.edu.cu TI Validación de un ELISA para la cuantificación de IgG humana anti-polisacarido capsular de Neisseria meningitidis serogrupo C DE anti-polysaccharide C ELISA DE Neisseria meningitidis DE polysaccharide C SO Biotecnología Aplicada 1999;16:113-115 AB An indirect ELISA against capsular polysaccharide of Neisseria meningitidis serogroup C was developed to evaluate the immune response to this component of VA-MENGOC-BC(r) Cuban vaccine. Polystyrene plates coated with poly-L-lysine and polysaccharide antigen ("Finlay" Institute), are first incubated with human serum samples. Antibodies are detected by addition of anti-human IgG/alkaline phosphatase conjugate, which recognizes antibodies against polysaccharide C. The enzymatic reaction is evidenced by processing of the specific substrate p-nitrophenylphosfate. The detection limit of the assay is 367 U/mL of specific IgG in human serum. Intra- and interassay lack of precision was below 10%. Parallelism, linearity and recovery were ± 10% of the expected values. The relation between the standard of the "Finlay" Institute and the PB2 standard from the Center for Disease Control (CDC), Atlanta, USA, was determined. The regression equation was CDC = 0.5398 Finlay +143 CC Article on Techniques CC Language: Spanish AU Javier Menéndez IN División de Biotecnología Industrial, Centro de Ingeniería Genética y Biotecnología. AP 6162, CP 10600. Ciudad de La Habana, Cuba. Fax: (53-7) 21 8070. E-mail: yeastlab@cigb.edu.cu TI Conventional and Non-conventional Yeasts in Modern Biotechnology SO Biotecnología Aplicada 1999;16:117-121 CC Report CC Language: English AU José A Cremata IN División de Biotecnología Industrial, Centro de Ingeniería Genética y Biotecnología. AP 6162, CP 10600. Ciudad de La Habana, Cuba. Fax: (53-7) 21 8070. E-mail: bioind@cigb.edu.cu TI Structural Analysis of Glycoproteins. Its Importance SO Biotecnología Aplicada 1999;16:121-125 CC Report CC Language: English AU Peter Aleström, José de la Fuente IN Department of Biochemistry, Physiology and Nutrition, Norwegian College of Veterinary Medicine. PO Box 8146 DEP, N-0033 Oslo, Norway. División de Genética de Células de Mamíferos, Centro de Ingeniería Genética y Biotecnología. AP 6162, CP 10600, Ciudad de La Habana, Cuba. Telef: (53-7) 21 8164; Fax: (53-7) 21 8070; E-mail: jose.delafuente@cigb.edu.cu TI Genetically Modified Fish in Aquaculture: Technical, Environmental and Management Considerations DE aquaculture DE fish DE safety DE transgenic SO Biotecnología Aplicada 1999;16:127-130 AB Genetically modified (GM) fish offer new possibilities for the improvement of production in aquaculture. It allows the introduction of novel traits or the improvement of old ones, in such a way that is out of reach for classical selection breeding. Examples of genes with commercial potential are among those which control growth, disease resistance, freeze tolerance, sexual maturation, food quality and food preservation parameters. Consumption of GM fish does not represent a health risk in principle. The safety of GM food is dependent on the character of the transgene, the transgene product and the new phenotype. Ethics and animal protection concerns demand the development of healthy fish only. Environmental safety calls for efficient biological containment in order to minimize possible effects caused by released farm animals. Improvements of disease control will support both production economy and the environment, in case of escapes. Since aquaculture includes both marine and fresh water species, it can be developed as new food production strategies in most countries all over the world. To avoid large-scale technology transfer failures, it is important to adapt to the regional and local needs. This calls for international research collaboration aiming at regional and local competence development sufficient for the technology implementation CC Focus CC Language: English